Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
| Treament |
Trials |
|
|
| clinical deterioration | clinical improvement | deaths | viral clearance |
| A EFFACER BBV152 (Bharat Biotech, India) | 0 | - | - | - | - | |
| A EFFACER Janssen Ad.26.COV2.S vaccine (JNJ-78436725) | 0 | - | - | - | - | |
| A EFFACER_ Vero cell | 0 | - | - | - | - | |
| A EFFACER_sequential Immunization | 0 | - | - | - | - | |
| BCG vaccination | 0 | - | - | - | - | |
| complete primary vaccine series | 0 | - | - | - | - | |
| CoVLP (MT-2766, Medicago) | 0 | - | - | - | - | |
| DNA vaccine | 0 | - | - | - | - | |
| ebola vaccine | 0 | - | - | - | - | |
| first booster dose | 0 | - | - | - | - | |
| heterologous prime-boost | 0 | - | - | - | - | |
| Inactivated virus vaccine | 0 | - | - | - | - | |
| mRNA vaccine | 0 | - | - | - | - | |
| Non replicating viral vector | 0 | - | - | - | - | |
| protein subunit vaccine | 0 | - | - | - | - | |
| Replicating Viral Vector | 0 | - | - | - | - | |
| seasonal influenza vaccines | 0 | - | - | - | - | |
| second booster dose | 0 | - | - | - | - | |
| virus-like particles vaccine | 0 | - | - | - | - | |
